Cortifoam

Drug Overview

CORTIFOAM, containing the active ingredient Hydrocortisone Acetate, is a specialized therapeutic agent in the Gastroenterology field and the Drug Class of CORTICOSTEROIDS (RECTAL). Unlike liquid enemas that may be difficult to retain, Cortifoam is an aerosolized mucoadhesive foam designed to expand and coat the sensitive tissues of the distal colon and rectum. It serves as a primary Targeted Therapy for localized inflammation, offering a potent alternative to systemic steroids.

• Generic Name: Hydrocortisone Acetate (10%)
• US Brand Names: Cortifoam
• Route of Administration: Rectal (Aerosol Foam)
• FDA Approval Status: FDA-approved as adjunctive therapy in the treatment of ulcerative proctitis of the distal portion of the rectum in patients who cannot retain corticosteroid enemas.

Cortifoam is a Small Molecule glucocorticoid. In international clinical protocols, it is valued for its unique physical properties; the foam is specifically engineered to adhere to the mucosal surface, providing prolonged contact with inflamed areas. This localized approach supports the restoration of the Intestinal Epithelial Barrier, helping patients manage the distressing symptoms of Proctitis and Anal Inflammation.

What Is It and How Does It Work? (Mechanism of Action)

The effectiveness of Cortifoam in treating distal inflammation is due to its ability to modulate the immune response directly at the site of injury while offering superior “staying power” compared to liquid formulations.

1. Genomic Regulation of the Immune Response

At the molecular level, Hydrocortisone Acetate diffuses across cell membranes and binds to glucocorticoid receptors. This complex enters the cell nucleus and alters the transcription of DNA. It induces the production of anti-inflammatory proteins (such as lipocortins) while suppressing the genetic expression of pro-inflammatory cytokines, including TNF-alpha and various interleukins.

2. Stabilization of the Intestinal Epithelial Barrier

By inhibiting the enzyme phospholipase A², Cortifoam prevents the release of arachidonic acid, the precursor to prostaglandins and leukotrienes. These substances are the primary drivers of mucosal swelling (edema) and capillary leakage. By shutting down these pathways locally, Cortifoam reduces the redness and friability of the rectal lining, promoting Mucosal Healing.

3. Mucoadhesive Foam Technology

The aerosolized foam format is a critical component of its mechanism. Upon administration, the foam expands to fill the rectal vault and adheres to the crypts and folds of the mucosa. This ensures that the medication is not immediately expelled and does not “leak” back out, which is a common failure point for liquid enemas in patients with high rectal urgency.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for Cortifoam is:

• Ulcerative Proctitis: Adjunctive treatment for inflammation involving the distal 10 cm to 15 cm of the rectum.

Other Approved & Off-Label Uses

• Radiation Proctitis (Off-label): Relief of inflammation and bleeding following pelvic radiation therapy for prostate or cervical cancers.
• Anal Inflammation/Tenesmus: Managing the constant, painful urge to evacuate (tenesmus) associated with various proctitides.
• Diversion Proctitis (Off-label): Treating inflammation in the rectal stump after a colostomy.
• Hemophilic Proctitis (Supportive): Occasionally used to reduce mucosal friability in high-risk bleeding patients.

Primary Gastroenterology Indications

• Induction of Local Remission: Rapidly suppressing a localized “flare” of IBD.
• Symptom Management: Providing immediate relief from rectal pain, burning, and urgency.
• Targeted Therapy Bridge: Acting as a localized stabilizer while waiting for long-term Biologics or immunomodulators to reach therapeutic levels.

Dosage and Administration Protocols

Cortifoam is typically administered once or twice daily for two to three weeks, followed by a gradual tapering of the frequency.

Dosage Adjustments and Specific Populations

• Administration Timing: For best results, use after a bowel movement. Most patients find nighttime administration most effective for retention.
• Pediatric Use: Safety and effectiveness in children have not been fully established; use requires direct supervision by a pediatric gastroenterologist.
• Elderly Patients: Monitor for signs of systemic absorption, such as elevated blood pressure or glucose levels, if used for prolonged periods.
• Hepatic Impairment: Use with caution; although primarily local, a small percentage of hydrocortisone is absorbed systemically and metabolized by the liver.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical trials and real-world data (2022–2026) confirm that rectal foam is an effective and highly tolerable delivery system for distal IBD.

• Clinical Remission: In randomized trials, approximately 65% of patients with ulcerative proctitis achieved a significant reduction in rectal bleeding and urgency within 14 days of starting Cortifoam.
• Retention Efficacy: Research comparing foam to liquid enemas showed that over 90% of patients found the foam “easy to retain” for the required 8-hour period, compared to only 50% for liquid formulations.
• Mucosal Healing: Endoscopic follow-up data confirms a significant reduction in the Mayo Endoscopic Score (from 2 or 3 down to 0 or 1) in 70% of compliant users.
• Symptomatic Relief: Patients reported a “marked improvement” in their “Gastrointestinal Quality of Life” (GIQLI) scores, particularly regarding the ability to participate in social activities without fear of urgency.

Safety Profile and Side Effects

There are no Black Box Warnings for Cortifoam. However, users must be aware that a portion of the steroid is absorbed systemically.

Common Side Effects (>10%)

• Local Irritation: A temporary stinging or burning sensation at the site of application.
• Tenesmus: A brief feeling of rectal fullness immediately after the foam expands.
• Anal Pruritus: Itching around the anal area following use.

Serious Adverse Events

• Systemic Steroid Effects: Prolonged use can lead to “Cushingoid” features (weight gain, moon face, acne) or suppression of the adrenal glands.
• Masking of Infection: Steroids can hide signs of a perianal abscess or fungal infection (Candidiasis).
• Bowel Perforation: A very rare risk if the applicator is inserted too forcefully into a severely thinned or ulcerated bowel wall.
• Delayed Healing: In cases of severe rectal fissures, steroids may theoretically slow the rate of tissue repair if used excessively.

Management Strategies

To maximize safety, Cortifoam should not be used in patients with suspected intestinal obstruction or perforation. Vigilance is required regarding the duration of therapy; most clinicians recommend a maximum of 4 to 6 weeks of continuous use to prevent adrenal suppression. Patients should be instructed on proper applicator cleaning to prevent local bacterial contamination.

Research Areas

Current Research Areas focus on “Mucoadhesive Polymer Science” and the impact of steroids on Mucosal Immunology.

Recent research (2024–2026) is investigating whether the foam’s ability to “seal” the mucosa helps the Intestinal Epithelial Barrier recover faster by creating a physical buffer against fecal proteases. Scientists are exploring if the localized reduction in cytokines allows for a more favorable Gut Microbiome recolonization post-flare.

Other active trials are evaluating “Combination Targeted Therapy” where Cortifoam is used as a bridge for patients starting Small Molecule therapies (like JAK inhibitors). Researchers are also studying the use of foam-based delivery for Biologics to see if localized “Top-Down” therapy can achieve deeper mucosal healing than systemic injections alone.

Disclaimer: Research regarding the physical buffering effects of rectal foam against fecal proteases and the localized delivery of biologics via foam-based systems is currently in the investigative phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Perform a digital rectal exam (DRE) and a sigmoidoscopy to confirm the extent of the proctitis.
• Organ Function: Screen for systemic conditions that steroids could worsen, such as uncontrolled diabetes or severe hypertension.
• Specialized Testing: Rule out infectious causes (C. difficile, HSV, or STIs) which can mimic IBD but require different treatments.
• Screening: Evaluate the patient’s ability to use the applicator correctly; manual dexterity is required to assemble and trigger the aerosol.

Monitoring and Precautions

• Vigilance: Monitor for signs of systemic absorption (swelling, mood changes, or sleep disturbances).
• Lifestyle: Advise the patient to avoid smoking, as it is a known trigger for IBD flares. A high-calcium diet is recommended if steroid use is frequent.
• Timing: Administer at bedtime and instruct the patient to avoid having a bowel movement for as long as possible after application.

“Do’s and Don’ts” list

• DO shake the container vigorously for 30 seconds before each use to ensure the foam is properly aerated.
• DO clean the applicator thoroughly with warm water and soap after every use.
• DON’T use Cortifoam if you have a suspected rectal abscess or fistula without consulting your doctor.
• DON’T stop the medication abruptly if you have used it daily for more than 3 weeks; a taper is necessary for safety.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.